NCT07724587 The Effectiveness and Safety of Combined Research on Uremic Sarcopenia
| NCT ID | NCT07724587 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ningbo Medical Center Lihuili Hospital |
| Condition | Sarcopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 76 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 76 participants in total. It began in 2025-09-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Objective: To investigate the clinical efficacy and safety of mindfulness meditation during dialysis combined with pre-dialysis progressive resistance training (PRT) for sarcopenia in patients undergoing maintenance hemodialysis (MHD). Methods: In the randomized controlled trial, 76 MHD patients with sarcopenia were divided into three groups: control group (CG), sports group (SG), and intervention group (IG). All groups received standard dialysis, health education, and dietary guidance. The SG received pre-dialysis PRT, while the IG added mindfulness meditation during dialysis. Efficacy and safety were evaluated at baseline and after 12 weeks. Ultrasound assessments of muscle mass were conducted at baseline, week 4, week 8, and week 12.
Eligibility Criteria
Inclusion Criteria: * Meet the updated Asian diagnostic criteria for sarcopenia * Stable vital signs and general physical condition * Willing and able to cooperate with supervised exercise training * Regular hemodialysis 3 times per week for at least 3 months Exclusion Criteria: * Acute cardiovascular or cerebrovascular events within the previous 3 months * Cognitive dysfunction affecting study cooperation and exercise completion * Severe osteoarticular or limb movement disorders preventing standardized exercise training * Active systemic infection
Contact & Investigator
yongyao wu
PRINCIPAL INVESTIGATOR
Department of Nephrology, Ningbo Medical Center Li Huili Hospital
Frequently Asked Questions
Who can join the NCT07724587 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07724587 currently recruiting?
Yes, NCT07724587 is actively recruiting participants. Contact the research team at wuyongyao.12345@163.com for enrollment information.
Where is the NCT07724587 trial being conducted?
This trial is being conducted at Ningbo, China.
Who is sponsoring the NCT07724587 clinical trial?
NCT07724587 is sponsored by Ningbo Medical Center Lihuili Hospital. The principal investigator is yongyao wu at Department of Nephrology, Ningbo Medical Center Li Huili Hospital. The trial plans to enroll 76 participants.